The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Reflexion Medical
A phase II randomized trial of RAdium-223 dichloride and SABR versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
 
Matthew Pierre Deek
No Relationships to Disclose
 
Hamza Hasan
No Relationships to Disclose
 
Ryan Phillips
No Relationships to Disclose
 
Robert F Hobbs
No Relationships to Disclose
 
Ana Ponce Kiess
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
Elizabeth D Thompson
No Relationships to Disclose
 
Jonathan Powell
No Relationships to Disclose
 
Curtiland Deville
No Relationships to Disclose
 
Stephen C. Greco
No Relationships to Disclose
 
Danny Song
No Relationships to Disclose
 
Steven P. Rowe
No Relationships to Disclose
 
Samuel R. Denmeade
Stock and Other Ownership Interests - Sophiris Bio
Consulting or Advisory Role - Sophiris Bio
Travel, Accommodations, Expenses - Sophiris Bio
 
Mark Christopher Markowski
Honoraria - Clovis Oncology; Exelixis
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Michael Anthony Carducci
Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst)
 
Mario A. Eisenberger
Leadership - Veru
Stock and Other Ownership Interests - Veru; Veru; Veru; Veru
Honoraria - pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; pfizer; Sanofi; Sanofi
Research Funding - Genentech; Sanofi; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Pfizer; Sanofi; Veru
 
Kenneth J. Pienta
Leadership - CUE Biopharma
Stock and Other Ownership Interests - CUE Biopharma; GreenMark Biomedical; Medsyn Biopharma; Oncopia Therapeutics
Honoraria - Johnson & Johnson; Progenics
Consulting or Advisory Role - Akrevia Therapeutics; Clinomics; CUE Biopharma; GloriousMed Technology
Research Funding - Progenics
Travel, Accommodations, Expenses - CUE Biopharma
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon; Omnitura
Research Funding - Lilly (Inst)
 
Phuoc T. Tran
Honoraria - Reflexion Medical
Consulting or Advisory Role - Astellas Pharma; Dendreon; GenomeDx; Noxopharm; Reflexion Medical; Reflexion Medical; Regeneron
Research Funding - Astellas Pharma (Inst); Bayer Health (Inst); Reflexion Medical (Inst)
Patents, Royalties, Other Intellectual Property - Compounds and Methods of Use in Ablative Radiotherapy. Patent filed 3/9/2012. PCT/US2012/028475. PCT/WO/2012/122471.
Travel, Accommodations, Expenses - Reflexion Medical